FreshPatents.com Logo

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Immunomedics Inc
Immunomedics Inc_20100114
Immunomedics Inc_20100121

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Immunomedics, Inc. patents


      
Recent patent applications related to Immunomedics, Inc.. Immunomedics, Inc. is listed as an Agent/Assignee. Note: Immunomedics, Inc. may have other listings under different names/spellings. We're not affiliated with Immunomedics, Inc., we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Immunomedics, Inc.-related inventors



Search recent Press Releases: Immunomedics, Inc.-related press releases
Count Application # Date Immunomedics, Inc. patents (updated weekly) - BOOKMARK this page
12014019335907/10/14Ultrafiltration concentration of allotype selected antibodies for small-volume administration
22014017829406/26/14Ultrafiltration concentration of allotype selected antibodies for small-volume administration
32014017006506/19/14Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
42014015427306/05/14Anthracycline-antibody conjugates for cancer therapy
52014014738205/29/14Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
62014014092405/22/14Humanized l243 antibodies
72014014092405/22/14Humanized l243 antibodies
82014012003505/01/14Rs7 antibodies
92014012003505/01/14Rs7 antibodies
102014011286404/24/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
112014011286504/24/14Anti-cd19 antibodies
122014011286404/24/14Anti-mucin antibodies for early detection and treatment of pancreatic cancer
132014011286504/24/14Anti-cd19 antibodies
142014010581904/17/14In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
152014010581904/17/14In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
162014009925804/10/14Camptothecin-binding moiety conjugates
172014009925804/10/14Camptothecin-binding moiety conjugates
182014009925804/10/14Camptothecin-binding moiety conjugates
192014008683003/27/14Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
202014008683203/27/14Delivery system for cytotoxic drugs by bispecific antibody pretargeting
212014008683003/27/14Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
222014008683203/27/14Delivery system for cytotoxic drugs by bispecific antibody pretargeting
232014007962903/20/14Class i anti-cea antibodies and uses thereof
242014007962903/20/14Class i anti-cea antibodies and uses thereof
252014005806702/27/14Immunoconjugates with an intracellularly-cleavable linkage
262014004463902/13/14Antibody therapy
272014004464002/13/14Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
282014003754302/06/14Anti-pancreatic cancer antibodies
292014003826102/06/14Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
302014003828402/06/14Mammalian cell lines for increasing longevity and protein yield from a cell culture
312014001716801/16/14Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
322014001719701/16/14Anti-cd19 antibodies
332014000407801/02/14Immunoconjugates with an intracellularly-cleavable linkage
342013031582111/28/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
352013030917711/21/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
362013021656108/22/13Immunoconjugates with an intracellularly-cleavable linkage
372013021656108/22/13Immunoconjugates with an intracellularly-cleavable linkage
382013020935608/15/13Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
392013021104408/15/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
402013020935608/15/13Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
412013021104408/15/13Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
422013017749807/11/13Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
432013017752607/11/13Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
442013017749807/11/13Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
452013017752607/11/13Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
462013017106407/04/13Anti-cd74 immunoconjugates and methods of use
472013017106507/04/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
482013017117607/04/13Anthracycline-antibody conjugates for cancer therapy
492013017106407/04/13Anti-cd74 immunoconjugates and methods of use
502013017106507/04/13In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
512013017117607/04/13Anthracycline-antibody conjugates for cancer therapy
522013016421406/27/13Antibody-based depletion of antigen-presenting cells and dendritic cells
532013016478306/27/13Mammalian cell lines for increasing longevity and protein yield from a cell culture
542013016421406/27/13Antibody-based depletion of antigen-presenting cells and dendritic cells
552013016478306/27/13Mammalian cell lines for increasing longevity and protein yield from a cell culture
562013015669106/20/13Antibody therapy
572013015669106/20/13Antibody therapy
582013014278706/06/13Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
592013014329606/06/13Delivery system for cytotoxic drugs by bispecific antibody pretargeting
602013014278706/06/13Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
612013014329606/06/13Delivery system for cytotoxic drugs by bispecific antibody pretargeting
622013012191305/16/13Anti-cd19 antibodies
632013012347305/16/13Bispecific antibody targeting a complement factor or complement regulatory protein
642013012191305/16/13Anti-cd19 antibodies
652013012347305/16/13Bispecific antibody targeting a complement factor or complement regulatory protein
662013009503404/18/13Anti-cd74 immunoconjugates and methods
672013009045804/11/13Immunoconjugates with an intracellularly-cleavable linkage
682013007818203/28/13Structural variants of antibodies for improved therapeutic characteristics
692013007826303/28/13Anti-hla-dr antibodies suppress allogeneic and xenogeneic immune responses to organ transplants
702013007132003/21/13Immunotherapy of autoimmune disorders using antibodies which target b-cells
712013007140603/21/13Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
722013007265903/21/13Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
732013003986102/14/13Dye conjugated peptides for fluorescent imaging
742013003449202/07/13Class i anti-cea antibodies and uses thereof
752012032856412/27/12Camptothecin-binding moiety conjugates
762012032863412/27/12Immunoconjugates with an intracellularly-cleavable linkage
772012032155312/20/12Ultrafiltration concentration of allotype selected antibodies for small-volume administration
782012028217811/08/12Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
792012027610011/01/12Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
802012023095309/13/12Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
812012021496908/23/12Methods and compositions for f-18 labeling of proteins, peptides and other molecules
822012019632608/02/12Mammalian cell lines for increasing longevity and protein yield from a cell culture
832012018954207/26/12Anti-cd19 antibodies
842012018347207/19/12Immunotherapy of b-cell malignancies using anti-cd22 antibodies
852012018355007/19/12Therapeutic using a bispecific antibody
862012014908506/14/12Fusion proteins containing recombinant cytotoxic rnases
872012014137206/07/12Rs7 antibodies
882012014137506/07/12Anti-mucin antibodies for early detection and treatment of pancreatic cancer
892012013492005/31/12Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
902012011455605/10/12Immunotherapy of autoimmune disorders using antibodies which target b-cells
912012010723505/03/12Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
922012008829904/12/12Mammalian cell lines for increasing longevity and protein yield from a cell culture
932012008261704/05/12Immunoconjugates with an intracellularly-cleavable linkage
942012007672703/29/12In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
952012006399303/15/12Therapeutic and diagnostic conjugates for use with multispecific antibodies
962012003979702/16/12Antibody therapy
972012004043102/16/12Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
982012003418502/09/12Anti-cd20 antibodies and fusion proteins therof and methods of use
992011031153112/22/11Immunotherapy of autoimmune disorders using antibodies which target b-cells
1002011030563112/15/11Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
1012011030006612/08/11Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
1022011029351312/01/11Immunoconjugates with an intracellularly-cleavable linkage
1032011028691811/24/11Immunotherapy of autoimmune disorders using antibodies which target b-cells
1042011028080111/17/11Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1052011027470411/10/11Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
1062011025605310/20/11Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases
1072011024384110/06/11Antibody-based depletion of antigen-presenting cells and dendritic cells
1082011024454610/06/11Internalizing anti-cd74 antibodies and methods of use
1092011023630409/29/11Structural variants of antibodies for improved therapeutic characteristics
1102011023640409/29/11Methods for protein expression in mammalian cells in serum-free medium
1112011022940709/22/11Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1122011022364509/15/11Multivalent carriers of bi-specific antibodies
1132011019502308/11/11Internalizing anti-cd74 antibodies and methods of use
1142011018908508/04/11Antibody therapy
1152011018926808/04/11Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1162011017112607/14/11Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
1172011016507207/07/11Detection of early-stage pancreatic adenocarcinoma
1182011016507307/07/11Immunotherapy of b-cell malignancies using anti-cd22 antibodies
1192011011701005/19/11Methods and compositions for administering therapeutic and diagnostic agents
1202011011710505/19/11Method of treating immune disease using b-cell antibodies
1212011011085405/12/11Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1222011007623303/31/11Delivery system for cytotoxic drugs by bispecific antibody pretargeting
1232011007015503/24/11Anti-cd74 immunoconjugates and methods
1242011007015603/24/11Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
1252011006465303/17/11Class i anti-cea antibodies and uses thereof
1262011005248903/03/11Anti-cd19 antibodies
1272010031116212/09/10Mammalian cell lines for increasing longevity and protein yield from a cell culture
1282010028490611/11/10Internalizing anti-cd74 antibodies and methods of use
1292010027263610/28/10Anti-cd74 immunoconjugates and methods of use
1302010026649610/21/10Anti-cd74 immunoconjugates and methods of use
1312010026649710/21/10Internalizing anti-cd74 antibodies and methods of use
1322010023377909/16/10Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1332010022688409/09/10Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
1342010022117509/02/10Antibody therapy
1352010022117709/02/10Rs7 antibodies
1362010021666208/26/10Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1372010020296108/12/10D-amino acid peptides
1382010019626608/05/10Humanized anti-hla-dr antibodies
1392010019626708/05/10Humanized l243 antibodies
1402010019698908/05/10Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1412010018964107/29/10Novel strategies for improved cancer vaccines
1422010015880206/24/10Chimeric, human and humanized anti-csap monoclonal antibodies
1432010015880306/24/10Production and use of novel peptide-based agents for use with bi-specific antibodies
1442010013662606/03/10Production and use of novel peptide-based agents for use with bi-specific antibodies
1452010010458904/29/10Immunoconjugates with an intracellularly-cleavable linkage
1462010007484003/25/10Anthracycline-antibody conjugates for cancer therapy
1472010006813603/18/10Anti-cd19 antibodies
1482010004054102/18/10Structural variants of antibodies for improved therapeutic characteristics
1492010003473802/11/10Structural variants of antibodies for improved therapeutic characteristics
1502010001504601/21/10Camptothecin-binding moiety conjugates
1512010001504801/21/10Internalizing anti-cd74 antibodies and methods of use
1522010000885501/14/10Production and use of novel peptide-based agents with bispecific antibodies
1532010000885801/14/10Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1542009030458012/10/09Anti-pancreatic cancer antibodies
1552009029903312/03/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1562009029109311/26/09Immunoconjugates with an intracellularly-cleavable linkage
1572009028575211/19/09Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
1582009027464911/05/09Bispecific antibody point mutations for enhancing rate of clearance
1592009025273110/08/09Multivalent carriers of bi-specific antibodies
1602009025317910/08/09Mammalian cell lines for increasing longevity and protein yield from a cell culture
1612009024613010/01/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1622009024613110/01/09Production and use of novel peptide-based agents for use with bi-specific antibodies
1632009024621410/01/09Fusion proteins containing recombinant cytotoxic rnases
1642009023875709/24/09Methods and compositions for administering therapeutic and diagnostic agents
1652009024003709/24/09Humanized antibodies and methods of humanizing antibodies
1662009018597407/23/09Chimeric, human and humanized anti-granulocyte antibodies and methods of use
1672009015516606/18/09Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1682009015525306/18/09Anti-cd20 antibodies and fusion proteins therof and methods of use
1692009011114304/30/09Methods and compositions for mammalian cell lines for transfection and protein expression in serum-free medium
1702009009259804/09/09Antibody therapy
1712010001504801/21/10Internalizing anti-cd74 antibodies and methods of use
1722010000885801/14/10Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Immunomedics, Inc. in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunomedics, Inc. with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         


FreshNews promo